注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

liusongjifan2的博客

读书是同智者交流;读书是对神奇世界的探访;读书是和挚友娓娓谈心 !

 
 
 

日志

 
 

【转载】The Lancet -Oncology  

2016-05-09 20:54:09|  分类: 医学知识 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |
Logo
Weekly Update
May 09, 2016
Weekly Features:
Steve Gschmeissner/Science Photo Library
Research | Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy
Adding short-term androgen suppression to salvage radiotherapy benefits men who have had radical prostatectomy and whose PSA rises after a postsurgical period when it is undetectable.
Read this Article →
The Lancet Choice
The Lancet Choice | Access any 5 articles from The Lancet Clinic for a reduced rate
The Lancet Choice gives you the flexibility to access any 5 paywall articles of your choice from The Lancet Clinic - all for the reduced introductory rate of $69.00.
Find out more →
Visit The Lancet Clinic →
Online First:
CNRI/Science Photo Library
NEWS
Ixazomib for multiple myeloma
Adding the oral proteasome inhibitor ixazomib to a regimen of lenalidomide and dexamethasone improves progression-free survival for patients with multiple myeloma, according to a new study.
Read this Report →
Steve Gshmeissner/Science Photo Library
NEWS
Surveillance benefit for pancreatic cancer in high-risk individuals
Surveillance of CDNK2A mutation carriers facilitates detection of pancreatic ductal adenocarcinoma (PDAC) at an early, resectable stage, according to a new study.
Read this Report →
NEWS
Bortezomib improves survival in rare myeloma
A phase 2 trial which enrolled 40 patients with the rare disease primary plasma cell leukaemia (PPCL; a type of multiple myeloma with a poor prognosis) has found that the addition of the proteasome inhibitor bortezomib to chemotherapy and autologous stem-cell transplantation significantly improved progression-free and overall survival compared to historical controls.
Read this Report →
ARTICLES
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis. Several studies have examined systemic chemotherapy with FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxaliplatin) in patients with locally advanced pancreatic cancer. This study aimed to assess the effectiveness of FOLFIRINOX as first-line treatment in this patient population.
Read this Article →
CC Studio/Science Photo Library
COMMENT
The smaller the better: a new concept in thoracic surgery?
Francesco Petrella and Lorenzo Spaggiari comment on the results of Morten Bendixen and colleagues' randomised controlled trial comparing postoperative pain and quality of life in patients with stage I non-small-cell lung cancer who underwent pulmonary lobectomy by video-assisted thoracic surgery (VATS) or anterolateral thoracotomy.
Read this Comment →
ARTICLES
Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial
Morten Bendixen and colleagues investigate postoperative pain and quality of life in a randomised trial of patients with early-stage non-small-cell lung cancer undergoing video-assisted thoracic surgery (VATS) versus open surgery.
Read this Article →
Steve Gschmeissner/Science Photo Library
COMMENT
Can short-term hormone therapy for rising PSA prolong survival?
Anthony D'Amico comments on Christian Carrie and colleagues' randomised study investigating the effect of adding androgen deprivation therapy to radiation therapy for PSA recurrence after radical prostatectomy on progression-free survival and overall survival.
Read this Comment →
ARTICLES
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial
This study aimed to establish the effect of adding short-term androgen suppression at the time of salvage radiotherapy on biochemical outcome and overall survival in men with rising PSA following radical prostatectomy.
Read this Article →
James Stevenson/Science Photo Library
COMMENT
Complete lymph node dissection in melanoma
Charlotte Ariyan comments on Ulrike Leiter and colleagues' trial of complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT).
Read this Comment →
ARTICLES
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
The DeCOG-SLT trial assessed whether complete lymph node dissection resulted in increased survival compared with observation.
Read this Article →
Science Photo Library
COMMENT
PI3K targeting in breast cancer: the end of the beginning?
Thomas Bachelot, Mario Campone, and Olivier Tredan comment on the findings of Ian Krop and colleagues' randomised study testing the addition of a PI3K inhibitor to second-line hormonal treatment for patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer.
Read this Comment →
ARTICLES
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
The aim of this study was to establish if addition of pictilisib to fulvestrant can improve progression-free survival in oestrogen receptor-positive, endocrine-resistant breast cancer.
Read this Article →
D Roberts/Science Photo Library
COMMENT
Immediate androgen deprivation: for all or for some?
Michael Leapman and Peter Carroll comment on the results of Gillian Duchesne and colleagues' multicentre, randomised trial comparing immediate androgen-deprivation therapy with delaying therapy by about 2 years.
Read this Comment →
ARTICLES
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Androgen-deprivation therapy is offered to men with prostate cancer who have a rising prostate-specific antigen after curative therapy (PSA relapse) or who are considered not suitable for curative treatment; however, the optimal timing for its introduction is uncertain. This study aimed to assess whether immediate androgen-deprivation therapy improves overall survival compared with delayed therapy.
Read this Article →
Astrid & Hanns-Frieder Michler/Science Photo Library
COMMENT
Encouraging results for PD-1 inhibition in gastric cancer
Elizabeth Smyth and David Cunningham comment on the results of the KEYNOTE-012 study.
Read this Comment →
ARTICLES
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Expression of PD-L1 has been shown to be upregulated in some patients with gastric cancer. Part of the phase 1b KEYNOTE-012 study assessed the safety and activity of the anti-PD-1 antibody pembrolizumab in patients with PD-L1-positive recurrent or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Read this Article →
Announcements:
Alerts
Stay Connected
You are receiving The Lancet Oncology Weekly Update as an extension to the Table of Contents alert service to which you are subscribed. 

If you would prefer not to receive these weekly updates, but wish to continue receiving the monthly Table of Contents alert, please click here:
Unsubscribe from Weekly Updates →

For all the very latest news, comment, and research follow The Lancet Oncology on Twitter.
Follow us →
Chicago skyline aerial view at dusk - marchello74
Attending ASCO in Chicago this June?
Visit us at the Elsevier booth #4031 to meet Isabel Lokody, Senior Editor ofThe Lancet Oncology and Lan-Lan Smith, Editor of The Lancet Haematology to discuss how to submit your research.

We’ll also be distributing free copies of The Lancet Oncology and special Commissions which highlight some of the key challenges and solutions in tackling the global cancer epidemic.
See you there! →
This email has been sent from The Lancet, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084. 

Copyright ? 2016 Elsevier Limited. All rights reserved. THE LANCET ? is a registered trademark of RELX Intellectual Properties SA, used under license. 

To unsubscribe from The Lancet Oncology Weekly Updates, but continue receiving the monthly Table of Contents alert, please click here →

To unsubscribe from all Table of Contents alerts, please edit your mailing preferences by logging in to your TheLancet.com account: 

Update mailing preferences
  评论这张
 
阅读(11)| 评论(0)
推荐 转载

历史上的今天

在LOFTER的更多文章

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017